1. Open LaboratoryDrugDiscovery at GSK: Collaboratingon Medicines forDiseases of theDevelopingWorld Martin Pan Discovery Medicine

2. Purpose of thisPresentation GSK CommitmenttoDiseases of theDevelopingWorld Introduce the Tres Cantos open laboratory concept Whatdoessuccess look like?

3. Our Mission To improve the quality of human life by enabling people to do more feel better live longer

4. The Challenge Africa has 24% global disease burden, but only 3% of the world’s health workers Healthcare spending (annual per capita) $34 - minimum required for fundamental healthcare <$12 - 35/46 countries in Africa spend $2,000 - high income countries Access to essential medicines <30% - Africa

5. GSK’s Response - Why? Ethical imperative Build a new, sustainable business model to address the needs and capabilities of the developing world Image and reputation imperative Demonstrate to financial institutions & external stakeholders effective GSK management of non-financial risks and thereby meet the expectations of society Business imperative Defend importance of IP framework for innovation Responsibly pursue commercial opportunities It’s the right thing to do for patients, society AND for our business

7. Knowledge Pool

8. Open lab

9. Malaria screen

10. TB, malaria

11. R&D PPPs

12. Knowledge Pool

13. APJEM R&D

14. Malaria vaccine

15. HIV

16. Tiered pricing

17. Price caps

18. MIC Pricing

19. Branded generics

20. 5% return on malaria vaccine

21. ViiV Healthcare

22. Brazil JV

23. AMC

24. CME

25. Voluntary licencing

26. 20% reinvestment

27. LF elimination

28. African malaria Partnership

29. PHASE

30. Positive Action and PAFC

32. GSK Diseases of the Developing World Focused on R&D in malaria, TB and other neglected diseases Collaborative with key funding partnerships Projects prioritised by unmet medical need - not commercial benefit Approx. 120 scientists in Tres Cantos Full access to GSK resources

33. What is our Vision for Tres Cantos? A campus that is recognised as a leading place to translate ideas into medicines for Diseases of the Developing World (DDW) The first port of call for any academic, institute or pharma company wishing to partner in drug discovery for DDW A pipeline of innovative transformational medicines for malaria, resistant TB and other Diseases of the Developing World

34. January, 2010

35. Open Innovation for Neglected Tropical Diseases Comprises three main strands: Being more flexible with our IP and know-how - Knowledge Pool Enabling access to our resources - open laboratory Opening up access to our compounds and data

38. Assures a minimum of pharmacologicalrequisites

39. Membranepermeability

40. Activityagainst target in itsintracellularcontext

41. Identification and validation of novel anti-malarial targetsMitochondrion Drug: Atovaquone Fidock, D.A. et al, Vol. 3, 2004, 509-520

42. Data-sharing: Release of 13,500 Malaria ChemicalStartingPoints > 2 Millioncompound GSK corporatecollectionscreenedforinhibitors of malaria parasite growth Wholecellapproachunder BSL3 containment Yearlongeffortinvolvingmultiplegroups at GSK Over 13,500 hits identified – structures and data releasedonwidelyaccessible internet sites Leadershipsteptoengageworldwidescientiststofullyexploit data and promoteneglecteddiseaseresearch Jumpstartresearchonurgentlyneeded novel antimalarialchemotypes and targets fordrugdiscovery 13

44. EMBL-EBI DatabaseforMining Malaria Compound Set www.ebi.ac.uk/chemblntd

45. Whatisthe Tres Cantos Open Lab? A concept intendedtofacilitate open collaborationbetween academia orotherinstitutions and GSK Anopportunityforexternalscientiststoworkalongside GSK drugdiscoveryscientists in Tres Cantos A wayfor GSK todemonstratecommitment and seek new approachesforstimulatingresearch in thefield of neglecteddiseases

46. General Principles of the Tres Cantos Open Lab Incomingprojectswillbealignedwithourinterests in TB, malaria orotherneglecteddiseases Projectswillbenefitfromthecollaborationwith DDW DrugDiscovery An open approachtoinnovation in neglecteddiseases (intellectualproperty)

47. High-level Operating Model for the Tres Cantos Open Lab Chair of the Governing Board Governing Board DDW Campus Head Open Lab Collaborations and Alliances

48. Tres Cantos Open Lab – `Open for Business´ First open laboratoryproject has started; othersbeingnegotiated In the short-term, successfor GSK willbethatwehavefosteredthescience and drugdiscovery in neglecteddiseases In thelonger-term, successfor GSK willbethatweplayedourpart in bringingtransformational new medicines topeoplewhoneedthem

49. Open Labpossibilitiesfor TB?

50. Open Architecture Approach to Research on Neglected Tropical Diseases Significant research funding devoted to neglected tropical diseases, but research largely fragmented Need for more concerted, collaborative approach to reduce redundancy and increase chance of success Neglected tropical disease research is an ideal area to explore innovative data sharing approaches Open architecture approach could be model for future pharmaceutical R&D 21

51. The over-arching priority ... Focus on the Patient